2014
DOI: 10.1016/j.humpath.2013.10.004
|View full text |Cite
|
Sign up to set email alerts
|

Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma

Abstract: Summary Distinction between primary intrahepatic cholangiocarcinoma (ICC) and metastatic pancreatic ductal adenocarcinoma (PDA) on a liver biopsy is essentially impossible histologically but has important clinical implications. In this study, 41 ICCs and 60 PDAs were immunohistochemically evaluated for the expression of S100P, pVHL, IMP3, maspin, MUC5AC, and CK17 proteins. The results showed pVHL expression in 29 (71%) ICCs but in only 3 (5%) PDAs. S100P, MUC5AC, and CK17 were frequently expressed in PDAs, see… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

3
54
1

Year Published

2015
2015
2019
2019

Publication Types

Select...
4
3

Relationship

1
6

Authors

Journals

citations
Cited by 70 publications
(58 citation statements)
references
References 28 publications
3
54
1
Order By: Relevance
“…Its overexpression has been observed in more than 90% of pancreatic ductal adenocarcinomas, [162][163][164][165][166][167] 76% of gallbladder adenocarcinomas, 168 and 76% to 92% of adenocarcinomas of extrahepatic bile ducts. 165,169,170 Interestingly, the frequency of S100P overexpression is much lower in intrahepatic cholangiocarcinomas, seen in only 27% in one study 167 and 48% in another study. 165 Malignant cells typically show strong nuclear or strong nuclear and cytoplasmic immunoreactivity, whereas benign epithelial cells are either completely nonreactive or show focal/patchy nuclear staining that is weaker in intensity compared with malignant cells (Figure 11, A).…”
Section: Immunomarkers To Distinguish Pancreaticobiliary Adenocarcinomentioning
confidence: 99%
See 3 more Smart Citations
“…Its overexpression has been observed in more than 90% of pancreatic ductal adenocarcinomas, [162][163][164][165][166][167] 76% of gallbladder adenocarcinomas, 168 and 76% to 92% of adenocarcinomas of extrahepatic bile ducts. 165,169,170 Interestingly, the frequency of S100P overexpression is much lower in intrahepatic cholangiocarcinomas, seen in only 27% in one study 167 and 48% in another study. 165 Malignant cells typically show strong nuclear or strong nuclear and cytoplasmic immunoreactivity, whereas benign epithelial cells are either completely nonreactive or show focal/patchy nuclear staining that is weaker in intensity compared with malignant cells (Figure 11, A).…”
Section: Immunomarkers To Distinguish Pancreaticobiliary Adenocarcinomentioning
confidence: 99%
“…Cytoplasmic positivity has been demonstrated in 71% to 97% of pancreatic ductal adenocarcinomas in various studies including cytology specimens, 162,167,[172][173][174][175][176][177] 82% of gallbladder adenocarcinomas, 168,178 and 50% to 92% of a d enoca rcino ma s o f ex tr a hep a tic b ile ducts. 169,170,[178][179][180] Intrahepatic cholangiocarcinomas also overexpress IMP3 at a high frequency (82%-90%), 167,181 but lower frequencies (37%-41%) are also reported. 178,182 In our experience, the greatest advantage of IMP3 is its high specificity for malignancy (Figure 11, B).…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…Better biomarkers are needed for the early detection of CCA. Immunohistochemical methods can be used to distinguish intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma [22]. The measurement of volatile organic compounds in biliary fluid is emerging as a possible method for diagnosing CCA in patients with PSC [23].…”
Section: Diagnosismentioning
confidence: 99%